GlassScriptPhysician profile
Kathryn Kirk
NPI 1477655371
$5,153.69
in general payments reported to CMS, 2019-2025
31 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $128 · 2021: $194 · 2022: $507 · 2023: $1,450 · 2024: $1,074 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,758 · Education: $19.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,757.72 |
| Education | $19.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,131.02 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $541.69 | 2019-2025 | Entyvio |
| Celgene Corporation | $413.41 | 2021-2024 | Zeposia |
| Pfizer INC. | $410.74 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $387.62 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $382.87 | 2019-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $225.43 | 2023-2025 | Omvoh, Zepbound |
| Qol Medical, LLC | $203.98 | 2023-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $191.32 | 2022-2025 | |
| Daiichi Sankyo INC. | $159.81 | 2019-2025 | Injectafer |
| Braintree Laboratories, INC. | $150.09 | 2019-2023 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $114.25 | 2019-2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $98.84 | 2022 | |
| Phathom Pharmaceuticals, INC. | $77.81 | 2023-2025 | Voquezna |
| Celltrion USA INC. | $77.44 | 2024-2025 | Vegzelma, Zymfentra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $74.49 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $71.31 | 2019-2025 | |
| Ardelyx, INC. | $67.53 | 2023-2024 | Ibsrela |
| Novo Nordisk INC | $47.17 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $43.32 | 2023 | |
| Fresenius Kabi USA, LLC | $42.23 | 2023 | Idacio |
| Ironwood Pharmaceuticals, INC | $39.58 | 2019-2024 | |
| Madrigal Pharmaceuticals | $39.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Vibrant Gastro, INC. | $38.70 | 2024 | Vibrant Starter Kit |
| Aimmune Therapeutics, INC. | $23.10 | 2025 | Zenpep |
| Orphalan INC | $23.04 | 2025 | Cuvrior |
| Pacira Pharmaceuticals Incorporated | $22.26 | 2023 | Exparel |
| Medtronic, INC. | $18.15 | 2021 | |
| Merck Sharp & Dohme LLC | $13.25 | 2019 | |
| Allergan, INC. | $12.61 | 2019 | |
| Boston Scientific Corporation | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.